Myrtucommulone, a natural acylphloroglucinol, inhibits microsomal prostaglandin E 2 synthase-1

British Journal of Pharmacology

Volumn 156, Issue 6, 2009, Pages 952-961

  Koeberle, A ^a   Pollastro, F ^b   Northoff, H ^c   Werz, O ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cyclooxygenase; Inflammation; Microsomal prostaglandin E 2 synthase 1; Natural products; NSAIDs; Prostaglandin E 2; Prostanoids

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MYRTUCOMMULONE; PROSTAGLANDIN E2; PROSTAGLANDIN E2 SYNTHASE 1; PROSTAGLANDIN H2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; 12 HYDROXY 5,8,10 HEPTADECATRIENOIC ACID; 12-HYDROXY-5,8,10-HEPTADECATRIENOIC ACID; DRUG DERIVATIVE; ISOMERASE; MYRTUCOMMULONE A; NONSTEROID ANTIINFLAMMATORY AGENT; PHLOROGLUCINOL; PROSTAGLANDIN E SYNTHASE; UNSATURATED FATTY ACID;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MICROSOME; MYRTLE; PLANT LEAF; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; BIOSYNTHESIS; BLOOD; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; TUMOR CELL LINE;

6-KETOPROSTAGLANDIN F1 ALPHA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE, TUMOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; FATTY ACIDS, UNSATURATED; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MICROSOMES; PHLOROGLUCINOL;

EID: 67650628023     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00070.x     Document Type: Article

References (41)

1. Albert D, Zundorf I, Dingermann T, Muller WE, Steinhilber D, Werz O (2002). Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol 64 : 1767 1775.
2. Appendino G, Bianchi F, Minassi A, Sterner O, Ballero M, Gibbons S (2002). Oligomeric acylphloroglucinols from myrtle (Myrtus communis). J Nat Prod 65 : 334 338.
3. Asano K, Lilly CM, Drazen JM (1996). Prostaglandin G/H synthase-2 is the constitutive and dominant isoform in cultured human lung epithelial cells. Am J Physiol 271 : L126 L131.
4. Bonjar GH (2004). Antibacterial screening of plants used in Iranian folkloric medicine. Fitoterapia 75 : 231 235.
5. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 : 248 254.
6. Brock TG, Lee YJ, Maydanski E, Marburger TL, Luo M, Paine R et al. (2005). Nuclear localization of leukotriene A4 hydrolase in type II alveolar epithelial cells in normal and fibrotic lung. Am J Physiol Lung Cell Mol Physiol 289 : L224 L232.
7. Capdevila JH, Morrow JD, Belosludtsev YY, Beauchamp DR, DuBois RN, Falck JR (1995). The catalytic outcomes of the constitutive and the mitogen inducible isoforms of prostaglandin H2 synthase are markedly affected by glutathione and glutathione peroxidase(s). Biochemistry 34 : 3325 3337.
8. Celotti F, Laufer S (2001). Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol Res 43 : 429 436.
9. Claveau D, Sirinyan M, Guay J, Gordon R, Chan CC, Bureau Y et al. (2003). Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J Immunol 170 : 4738 4744.
10. Cote B, Boulet L, Brideau C, Claveau D, Ethier D, Frenette R et al. (2007). Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett 17 : 6816 6820.
11. Engblom D, Saha S, Engstrom L, Westman M, Audoly LP, Jakobsson PJ et al. (2003). Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. Nat Neurosci 6 : 1137 1138.
12. Feisst C, Franke L, Appendino G, Werz O (2005). Identification of molecular targets of the oligomeric nonprenylated acylphloroglucinols from Myrtus communis and their implication as anti-inflammatory compounds. J Pharmacol Exp Ther 315 : 389 396.
13. Funk CD (2001). Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 : 1871 1875.
14. Gillard J, Ford-Hutchinson AW, Chan C, Charleson S, Denis D, Foster A et al. (1989). L-663,536 (MK-886) (3-(1-(4-chlorobenzyl)-3-t-butyl-thio-5- isopropylindol-2-yl)-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 67 : 456 464.
15. Guichardant M, Petit F, Lagarde M (1989). Metabolism of endogenous arachidonic acid in weakly activated platelets. Absence of leukocyte cooperative products in whole blood. Eicosanoids 2 : 117 121.
16. Jachak SM (2007). PGE synthase inhibitors as an alternative to COX-2 inhibitors. Curr Opin Investig Drugs 8 : 411 415.
17. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B (1999). Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 96 : 7220 7225.
18. Kapoor M, Kojima F, Qian M, Yang L, Crofford LJ (2006). Shunting of prostanoid biosynthesis in microsomal prostaglandin E synthase-1 null embryo fibroblasts: regulatory effects on inducible nitric oxide synthase expression and nitrite synthesis. FASEB J 20 : 2387 2389.
19. Kato K, Ohkawa S, Terao S, Terashita Z, Nishikawa K (1985). Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids. J Med Chem 28 : 287 294.
20. Koeberle A, Siemoneit U, Buehring U, Northoff H, Laufer S, Albrecht W et al. (2008). Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther 326 : 975 982.
21. Kojima F, Naraba H, Miyamoto S, Beppu M, Aoki H, Kawai S (2004). Membrane-associated prostaglandin E synthase-1 is upregulated by proinflammatory cytokines in chondrocytes from patients with osteoarthritis. Arthritis Res Ther 6 : R355 R365.
22. Levesque H, Lafont O (2000 Aspirin throughout the ages: a historical review Rev Med Interne 21 (Suppl. 1 8s 17s.
23. Mancini JA, Abramovitz M, Cox ME, Wong E, Charleson S, Perrier H et al. (1993). 5-Lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett 318 : 277 281.
24. Mancini JA, Blood K, Guay J, Gordon R, Claveau D, Chan CC et al. (2001). Cloning, expression, and up-regulation of inducible rat prostaglandin E synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. J Biol Chem 276 : 4469 4475.
25. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR (1993). Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90 : 11693 11697.
26. Murakami M, Nakatani Y, Tanioka T, Kudo I (2002). Prostaglandin E synthase. Prostaglandins Other Lipid Mediat 68-69 : 383 399.
27. Park JY, Pillinger MH, Abramson SB (2006). Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol 119 : 229 240.
28. Quraishi O, Mancini JA, Riendeau D (2002). Inhibition of inducible prostaglandin E(2) synthase by 15-deoxy-Delta(12,14)-prostaglandin J(2) and polyunsaturated fatty acids. Biochem Pharmacol 63 : 1183 1189.
29. Riendeau D, Aspiotis R, Ethier D, Gareau Y, Grimm EL, Guay J et al. (2005). Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg Med Chem Lett 15 : 3352 3355.
30. Romani A, Coinu R, Carta S, Pinelli P, Galardi C, Vincieri FF et al. (2004). Evaluation of antioxidant effect of different extracts of Myrtus communis L. Free Radic Res 38 : 97 103.
31. Rosa A, Deiana M, Casu V, Corona G, Appendino G, Bianchi F et al. (2003). Antioxidant activity of oligomeric acylphloroglucinols from Myrtus communis L. Free Radic Res 37 : 1013 1019.
32. Samuelsson B, Morgenstern R, Jakobsson PJ (2007). Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59 : 207 224.
33. Scholich K, Geisslinger G (2006). Is mPGES-1 a promising target for pain therapy? Trends Pharmacol Sci 27 : 399 401.
34. Smith WL (1989). The eicosanoids and their biochemical mechanisms of action. Biochem J 259 : 315 324.
35. Sugimoto Y, Narumiya S (2007). Prostaglandin E receptors. J Biol Chem 282 : 11613 11617.
36. Thoren S, Jakobsson PJ (2000). Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4. Eur J Biochem 267 : 6428 6434.
37. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP et al. (2003). Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA 100 : 9044 9049.
38. Tretiakova I, Blaesius D, Maxia L, Wesselborg S, Schulze-Osthoff K, Cinatl J et al. (2007). Myrtucommulone from Myrtus communis induces apoptosis in cancer cells via the mitochondrial pathway involving caspase-9. Apoptosis 13 : 119 131.
39. Trussardi A, Poitevin G, Gorisse MC, Faroux MJ, Bobichon H, Delvincourt C et al. (1998). Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells. Int J Oncol 13 : 543 548.
40. Xu D, Rowland SE, Clark P, Giroux A, Cote B, Guiral S et al. (2008). MF63 {2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)isophthalonitrile}, a selective microsomal prostaglandin E synthase 1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther 326 : 754 763.
41. Yamamoto S, Yokota K, Tonai T, Shono F, Hayashi Y (1987). Enzyme Immunoassay. Prostaglandins and Related Substances - a Practical Approach. IRL Press : Oxford.